Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Margin
Regeneron Pharmaceuticals Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
62.5B USD |
29%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
371.4B USD |
31%
|
|
| US |
U
|
US BioTec Inc
OTC:USBC
|
156.3B USD | N/A | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
158.1B USD |
31%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
142.9B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.7B USD |
39%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
104.9B AUD |
26%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
60.1B USD |
-7%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Regeneron Pharmaceuticals Inc
Glance View
In the vibrant world of biotechnology, Regeneron Pharmaceuticals Inc. emerged as a powerhouse by meticulously weaving together science and medicine. Founded in 1988 by a visionary team, including celebrated scientists Dr. Leonard Schleifer and Dr. George Yancopoulos, Regeneron was created with an ambitious mission to harness the power of biology to bring innovative medicines to patients. The company began its journey with a strong emphasis on research and development, evolving its unique approach to drug discovery focused on the rapid and precise identification of biologically relevant targets. With a strategic location at the heart of New York's biotechnology valley, Regeneron thrived, investing substantially in proprietary technologies and developing a robust pipeline of therapeutics aimed at addressing critical unmet medical needs across various domains such as ophthalmology, immunology, oncology, and rare diseases. Today, Regeneron makes its mark in the pharmaceutical industry primarily through its innovative product portfolio, comprised of renowned drugs like EYLEA, a leading treatment for retinal diseases, and Dupixent, a medication for atopic dermatitis and other allergic conditions. The company's revenue model relies heavily on the commercial success of these drugs, supported by strategic collaborations and partnerships with industry giants like Sanofi. Their success is driven by a commitment to leveraging cutting-edge technology platforms, such as the VelociSuite, which expedites drug discovery and development processes. Regeneron’s emphasis on precision and quality, coupled with an agile business model that adapts to health landscapes, allows it to maintain a competitive edge in a rapidly evolving industry while consistently delivering robust financial performance.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Regeneron Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of 28.6%.
You don't have any saved screeners yet